Notice of acceptance of patent in Australia

Patent acceptance in Australia marks procedural progress, but lacks financial impact or detail.

Risk flags

• ●The announcement does not disclose any financial data, such as revenue, profit, or cash position, preventing assessment of the company's financial health or the materiality of the patent to its business.
• ●Patent acceptance is procedural and does not guarantee grant or enforceability; administrative requirements and a three-month gazetting period remain, introducing the risk of delay or potential objections.
• ●No evidence is provided regarding the commercial relevance or market demand for the patented technology, leaving the potential for revenue generation unquantified and speculative.

Bottom line

This announcement signals procedural progress in Fusion Antibodies plc's intellectual property strategy, with the acceptance of a patent application in Australia. The company highlights operational achievements and a strong client roster, but provides no financial disclosures or evidence of commercial impact. The patent has not yet been granted, and any future benefits are contingent on administrative completion with no defined timeline or revenue prospects. For investors, this update is not actionable without further detail on financial performance or commercialisation plans. The most important takeaway is that while the patent process is advancing, its value to shareholders remains unproven and unquantified.

Announcement summary

(AIM: FAB) Fusion Antibodies plc announced that IP Australia has issued a notice of acceptance for the Company's Australian patent application no. 2019365135. The Patent Application, entitled "Antibody Library and Method", covers two families of antibodies and the methods for designing such antibody libraries. Fusion continues to progress additional patent applications in respect of the OptiMAL® Library in several other territories worldwide including Europe and China. Since 2012, the Company has successfully sequenced and/or expressed over 750 antibodies and completed over 250 humanisation projects. The company anticipates that the patent will be granted in due course, following completion of certain administrative requirements, including payment of the applicable fees, and the successful completion of a three-month gazetting period. Fusion's client base has included eight of the top 10 global pharmaceutical companies by revenue. The Company's ordinary shares were admitted to trading on AIM on 18 December 2017.

Disagree with this article?